

Remarks

The Examiner has restricted the claims into 4 groups. Applicants elect the compound claims of Group I which is directed to compounds of Formula I wherein Azabicyclo is I or IV.


Applicants also elect the species of Example 5 which is N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1H-pyrrolo[2,3-c]pyridine-5-carboxamide dihydrochloride.

Applicants acknowledge the Examiner's indication that the subject matter of Group III which is directed to methods of treatment using the compounds of Formula I wherein Azabicyclo is I or IV, will be rejoined if certain requirements are met. Applicants will amend claims 16-23 to place them in condition for rejoinder if there is opportunity upon subsequent prosecution. Otherwise, Applicants maintain the right to present such subject matter in a refiled application.

A Petition for a two month extension of time is enclosed. If any fees are missing or deficient, please charge our deposit account number 16-1445.

Respectfully submitted,

Date: Dec 16, 2005

  
**Eileen M. Ebel**  
Attorney for Applicant(s)  
Reg. No. 37,316

Pfizer Inc  
Patent Department, 5<sup>th</sup> Floor  
150 East 42nd Street  
New York, NY 10017  
(212) 733-0885